Biopraxis is developing a label-free microarray platform for drug discovery and development, high throughput screening of chemical libraries against protein, DNA, and RNA targets, genomics, chemoproteomics, and glycomics. Biopraxis is commercializing a solid-state biochip for detecting inorganics, organics, and microorganisms; an economical technology for treating heavy & radionuclide contamination; and a new approach for synthesizing low-cost catalysts. Biopraxis, Inc. develops microSERS, low-cost tools for rapidly analyzing large numbers of environmental and clinical samples for thousands of toxic compounds.
